Insurance Barriers Limit Children’s Access to Biologics for Asthma
-
By
-
Debbie Bunch
-
November 16, 2026
Clinical Report: Insurance Barriers Limit Children’s Access to Biologics for Asthma
Overview
A study presented at the American Academy of Allergy, Asthma and Immunology meeting reviewed 326 biologic prescriptions issued by allergists for children with asthma from 2018 through 2026. Nearly all prescriptions required insurance approval, about four in ten were denied, and children who received treatment generally waited more than a month after the prescription was written.
Background
Biologic therapies are used for some children with severe asthma, and the supplied 2026 Global Initiative for Asthma guidance advises considering add-on Type 2-targeted biologics for children and adolescents with severe asthma who remain uncontrolled despite optimized high-dose ICS–LABA and have evidence of Type 2 inflammation. U.S. labeling includes several biologics for pediatric asthma, with age eligibility varying by medication. The article reports that insurance authorization requirements can delay or prevent access to prescribed treatment. Its co-author Aarti Pandya, MD, said that delays may place children with uncontrolled asthma or allergies at risk for serious health problems.
Data Highlights
| Measure | Finding |
|---|---|
| Prescriptions reviewed | 326 |
| Study period | 2018–2026 |
| Mean patient age | 11 years |
| Male participants | Approximately half |
| Omalizumab prescriptions | 55.8% |
| Dupilumab prescriptions | 26% |
| Prescriptions requiring insurance approval | Nearly all |
| Prescriptions eventually denied | Approximately 4 in 10 |
| Time from prescription to treatment initiation among recipients | Generally more than one month |
Key Findings
- The study examined 326 biologic prescriptions written by allergists for pediatric patients between 2018 and 2026; mean age was 11 years, and approximately half the patients were male.
- Omalizumab accounted for 55.8% of prescriptions and dupilumab for 26%.
- Insurance approval was required before dispensing for nearly all prescriptions, and approximately four in ten prescriptions were ultimately denied.
- The most common reported denial reasons were requirements to try another medication first or failure to meet the insurer’s criteria for the prescribed drug.
- For children who received treatment, the interval from prescription to initiation generally exceeded one month; some families experienced longer waits.
- In related research, the supplied context reports that distribution problems were associated with greater biologic discontinuation among adults with moderate-to-severe psoriasis; it also describes pediatric biologic uptake research in immune-mediated inflammatory diseases and population-level research on asthma exacerbations after respiratory biologics were introduced.
Clinical Implications
The study authors said the findings support discussion of ways to streamline and accelerate prior authorization for pediatric asthma biologics. Pandya stated that each week matters when pediatric asthma or allergies are uncontrolled and that delays may place children at risk for serious health problems.
Conclusion
In this prescription review, insurance authorization was nearly universal, denials were common, and treatment initiation for recipients generally took more than a month. The authors called for discussion of changes to streamline and accelerate approvals.
Related Resources & Content
- Global Initiative for Asthma, GINA Strategy Report 2026 -- Global Strategy for Asthma Management and Prevention
- mdspire news, Year not provided -- Distribution Barriers May Reduce Biologic Drug Survival
- Pharmacoepidemiology and Drug Safety, Year not provided -- Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study
- JAMA Network Open, Year not provided -- Population-Level Trends in Asthma Exacerbations After Introduction of Respiratory Biologics
- RT, Year not provided -- Insurance Denials, Delays Limit Pediatric Asthma Biologics
- ASCO Publications — ReCAP: Gaps in Insurance Coverage for Pediatric Patients With Acute Lymphoblastic Leukemia
- GINA Strategy Report 2026
- Insurance Denials, Delays Limit Pediatric Asthma Biologics
- GINA Strategy Report 2026 Front Cover
- DailyMed - XOLAIR- omalizumab injection, solution XOLAIR PFS- omalizumab injection, solution XOLAIR- omalizumab injection, solution
- label
- Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE)
- Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study)
- Age-specific efficacy of biologics in severe asthma: a pediatric perspective
- Associations Between Social Determinants of Health and Adherence to Biologic Therapies in Patients with Severe Asthma: Real-World Evidence from a Large US Claims Analysis
- PRIOR AUTHORIZATION DISCREPANCIES AMONG STATE MEDICAID PROGRAMS FOR MEPOLIZUMAB
Based on findings from:
Insurance Companies Make It Difficult for Kids with Asthma to Get Biologics
Debbie Bunch. American Association For Respiratory Care, 2026.
https://rccentral.aarc.org/insurance-barriers-biologics-children-severe-asthma/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.